Research Topics
| Daniel A ValleraSummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibodyDaniel A Vallera
Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
Cancer Biother Radiopharm 22:488-500. 2007..Also, the final outcome may be impacted by the size of the PEG molecule used for the modification of the blood half-life...- A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphomaDaniel A Vallera
Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Cancer Center, Minneapolis, Minnesota, USA
Clin Cancer Res 11:3879-88. 2005..DT2219 has broader reactivity in recognizing B-cell malignancies, has more killing power, and requires less toxin than using individual immunotoxin, which warrants further investigation as a new drug for treating B leukemia/lymphoma... - Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in miceDaniel A Vallera
Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Section on Molecular Cancer Therapeutics, MMC 367, Minneapolis, MN 55455, USA
Leuk Res 29:331-41. 2005..Bic3 warrants investigation as a new drug for treating T-cell malignancy and other T-cell related disorders... - Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein geneDaniel A Vallera
University of Minnesota Cancer Center, Department of Therapeutic Radiology, Section on Experimental Cancer Immunology, Minneapolis, MN 55455, USA
Hum Gene Ther 14:1787-98. 2003..Furthermore, the Bax construct may be particularly useful as a nonimmunogenic substitute for bacterial toxins in retIT... - Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude miceD A Vallera
University of Minnesota Cancer Center, Department of Therapeutic Radiology Radiation Oncology, Minneapolis 55455, USA
Cancer Biother Radiopharm 18:133-45. 2003.... 
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft modelD A Vallera
University of Minnesota Cancer Center, Department of Therapeutic Radiology Radiation Oncology, Minneapolis, MN 55455, USA
Gut 57:634-41. 2008....- Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancyDaniel A Vallera
University of Minnesota Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, Minneapolis, MN 55455, USA
Leuk Res 33:1233-42. 2009..DT2219ARL represents a new class of bispecific biological that can be continually improved by genetic mutation... - Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastasesDaniel A Vallera
Masonic Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
Mol Cancer Ther 9:1872-83. 2010..Because 2219KDEL7mut immunogenicity was significantly reduced and the drug was highly effective in vivo, we can now give multiple drug treatments with targeted toxins in future clinical trials... - Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibodyDaniel A Vallera
Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, 55455, USA
Clin Cancer Res 11:7920-8. 2005..These findings indicate that anti-CD22 radioimmunotherapy with Y22 is highly effective in vivo against CD22-expressing malignancies and may be a useful therapy for drug-refractory B cell leukemia patients... - A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft modelDeborah A Todhunter
Department of Neurosurgery, University of Minnesota Cancer Center, Minneapolis 55455, USA
Protein Eng Des Sel 17:157-64. 2004..These findings indicate that bispecific IT may allow treatment of a broader subset of antigenically diverse patients while simultaneously reducing the exposure to toxin required than if two separate agents were employed... - Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient miceEdward Rustamzadeh
Department of Neurosurgery, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
Int J Cancer 120:411-9. 2007..These results suggest that the DTAT recombinant fusion protein is highly effective in an intracranial model and DTAT might be an effective treatment for glioblastoma... - Efficacy of antiangiogenic targeted toxins against glioblastoma multiformeWalter A Hall
Department of Neurosurgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA
Neurosurg Focus 20:E23. 2006..Another protein, DTAT13, was synthesized to target uPAR on the neovasculature and the uPAR and interleukin-13 receptor-expressing GBM cells. The authors describe the in vitro and in vivo efficacy of DTAT and DTAT13 against GBM... 
Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced deliverySeunguk Oh
Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Masonic Cancer Center, MMC 367, Minneapolis, MN 55455, USA
J Neurooncol 95:331-42. 2009..Thus, DTEGF13 is safe and efficacious as an alternative drug for glioblastoma therapy and warrants further study...- A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculatureAlexander K Tsai
Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Masonic Cancer Center, MMC 367, Minneapolis, MN 55455, USA
J Neurooncol 103:255-66. 2011..Thus, EGFATFKDEL 7mut is an effective drug for glioblastoma therapy in this murine model and warrants further study... - Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude miceChunbin Li
Department of Therapeutic Radiology-Radiation Oncology, Section on Experimental Cancer Immunology, University of Minnesota Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
Protein Eng 15:419-27. 2002..Together, these data suggest that DT(390)IL13 may provide an important, alternative therapy for brain cancer... - A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancerBrad J Stish
Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
Clin Cancer Res 13:6486-93. 2007.... - Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibodyDaniel A Vallera
Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN, USA
Cancer Biother Radiopharm 19:11-23. 2004..Because radiolabeled anti-CD19 antibody can be used to deliver radiation selectively to lymphohematopoietic tissue, these data support the use of 90Y anti-CD19 antibodies in treating B-cell malignancies... - Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13Edward Rustamzadeh
Department of Neurosurgery, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
J Neurooncol 77:257-66. 2006..These studies show that DTAT13 has properties encompassing those of both DTIL13 and DTAT and warrants further consideration for clinical development... - Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient miceEdward Rustamzadeh
Department of Neurosurgery, University of Minnesota Cancer Research Center, Minneapolis, MN 55455, USA
Int J Cancer 118:2594-601. 2006..These results suggest that DTIL13 is as effective in an intracranial rodent model as it was in a flank model in previous studies and that DTIL13 might be an effective treatment for glioblastoma multiforme... - Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft modelBrad J Stish
Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
J Neurooncol 87:51-61. 2008..These studies show that a new co-targeting agent that simultaneously recognizes EGFR and IL-13R is more effective than its monospecific counterparts and that DTEGF13 has therapeutic advantages for glioblastoma... - A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic modelSeunguk Oh
Department of Therapeutic Radiology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
Pancreas 41:789-96. 2012..The objective was to test a bispecific ligand-directed toxin (BLT), with reduced immunogenicity for enhanced efficacy in targeting orthotopic pancreatic cancer in vivo... - Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemiaQing Zhou
Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Blood 116:2484-93. 2010..PD-1/PD-L1 blockade coupled with Treg depletion represents an important new approach that can be readily translated into the clinic to improve the therapeutic efficacy of adoptive AML-reactive CTLs in advanced AML disease... - Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brainSeunguk Oh
Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Neurosurg 114:1662-71. 2011.... - Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancerNate N Waldron
Department of Pharmacology, Masonic Cancer Center, University of Minnesota, MMC 367, Minneapolis, MN 55455, USA
Mol Cancer Ther 10:1829-38. 2011..This agent shows significant promise for potential development as a clinically useful therapy... - Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFvBrad J Stish
Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
Clin Cancer Res 13:3058-67. 2007..The goal of this study was to determine if genetically adding an sFv targeting epithelial cell adhesion molecule (EpCAM) to an anti-Her2 sFv immunotoxin would result in enhanced antitumor activity... - A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinomaSeunguk Oh
Masonic Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
Clin Cancer Res 15:6137-47. 2009..Our purpose was to reduce toxin immunogenicity using mutagenesis, measure the ability of mutated drug to elicit B-cell antitoxin antibody responses, and show that mutated drug was effective against systemic breast cancer in vivo... - A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancerSeunguk Oh
Therapeutic Radiology and daggerSurgery, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
Pancreas 39:913-22. 2010.... - Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiformeEdward Rustamzadeh
Department of Neurosurgery, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
J Neurooncol 65:63-75. 2003..In this article, we review our progress to date with DTAT... - Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTATDaniel A Vallera
Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis 55455, USA
J Natl Cancer Inst 94:597-606. 2002.... - Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor--immunotoxin target geneNi Jin
Section on Experimental Cancer Immunology, Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
Hum Gene Ther 13:497-508. 2002..Together, these data indicate that gene therapy of T cells with retrovirus containing a VEGF-immunotoxin target gene may be a valid means of inhibiting a broad range of solid tumors dependent on angiogenesis... - Lack of GVHD across classical, single minor histocompatibiliTy (miH) locus barriers in miceB R Blazar
Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Hospital and Clinic, Minneapolis 55455, USA
Transplantation 61:619-24. 1996..These results suggest a rapid downregulation or disappearance of miH antigen-reactive CTL after BMT. These data have implications for the use of in vitro assays to predict GVHD risk in recipients of miH loci-disparate donor grafts... - Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemiaQing Zhou
Department of Pediatrics, Division of Blood and Marrow Transplantation, Masonic Cancer Center, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA
Blood 114:3793-802. 2009.... - Recent advances in graft-versus-host disease (GVHD) preventionB R Blazar
Department of Pediatrics, University of Minnesota Hospital and Clinics, Minneapolis 55455, USA
Immunol Rev 157:79-109. 1997..Collectively, these approaches are illustratrative of the progress made in extending our GVHD prevention armamentarium... - The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamideA Panoskaltsis-Mortari
Department of Pediatrics, BMT Division, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Clin Invest 100:1015-27. 1997..This demonstration of early injury after BMT indicates the need for very early therapeutic intervention before lung damage becomes profound and irreversible... - Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigenB R Blazar
Department of Pediatrics, University of Minnesota Hospital, Minneapolis 55455, USA
J Immunol 159:5821-33. 1997..These data have implications for designing therapeutic approaches directed toward TCR targeting in humans... - CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responsesB R Blazar
Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
J Clin Invest 102:473-82. 1998..T cells had intact responses to antigens not present during tolerization. Tolerance was long lived and not readily reversible in vivo. These data have significant implications for the use of tolerization approaches to prevent human GVHD... - A critical role for CD48 antigen in regulating alloengraftment and lymphohematopoietic recovery after bone marrow transplantationB R Blazar
University of Minnesota Cancer Center and the Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota Hospital, Minneapolis, MN, USA
Blood 92:4453-63. 1998..Taken together, these data provide evidence that the CD48 antigen plays a critical role in regulating hematopoiesis in post-BMT... - Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin geneD A Vallera
University of Minnesota Cancer Center, Department of Therapeutic Radiology, Minneapolis 55455, USA
Cancer Res 60:976-84. 2000.... - Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine modelD A Vallera
Departments of Therapeutic Radiology, Section on Experimental Cancer Immunology and Pediatrics, Division of Bone Marrow Transplantation University of Minnesota Cancer Center, Minneapolis, USA
Blood 96:1157-65. 2000.... - Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in miceA Panoskaltsis-Mortari
University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, Minneapolis, USA
Blood 92:3960-7. 1998..These studies demonstrate that KGF administration, completed before conditioning, has potential as an anti-GVHD therapeutic agent... - Immunotoxin therapy for CNS tumorEdward Rustamzadeh
Department of Neurosurgery, Graduate School, University of Minnesota, Minneapolis, MN, USA
J Neurooncol 64:101-16. 2003..In this review article the history, design, toxicity, and pharmokinetics of immunotoxins will be discussed in detail... - Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activityB J Stish
Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
Br J Cancer 101:1114-23. 2009..Potency, immunogenicity, and toxicity are three problems that limit the use of targeted toxins in solid tumour therapy... - Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine productionMichelle K Gleason
Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA
Mol Cancer Ther 11:2674-84. 2012.... - Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinomaNate N Waldron
University of Minnesota, Department of Pharmacology, Minneapolis, MN 55455, USA
Oral Oncol 48:1202-7. 2012..To investigate the efficacy of the bispecific targeted toxin, dEGFATFKDEL, on head and neck carcinoma cell lines in vitro and in vivo... - Peptide toxins directed at the matrix dissolution systems of cancer cellsArthur E Frankel
Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
Protein Pept Lett 9:1-14. 2002..These recombinant fusion proteins provide a novel class of anti-cancer agents that will enter clinical trials in the next several years... - Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion proteinArthur E Frankel
Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Exp Hematol 30:1316-23. 2002..The work also suggests that blast proliferation assays yield similar responses to leukemia colony-forming cell colony assays... - The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cellsJason G Ramage
Department of Cancer Biology, Wake Forest University School of Medicine, Medical Center Boulevard, 27157, Winston Salem, NC, USA
Leuk Res 27:79-84. 2003....